

Delivering results

Welcome to two new **Publishing Partners** for 2012



The University of Liverpool is a member of the Russell Group of leading research universities and accredited by the Quality Assurance Agency for Higher Education (QAA). It is at the forefront of higher education in the UK and now with over 10 years' experience of online experience, is (in partnership with Laureate International Universities) now the largest provider of 100% online postgraduate degrees in Europe.

Programmes are designed for working professionals who are seeking career advancement, personal development, and a strengthening of their skills and knowledge in an international environment. Today, over 6500 working professionals from more than 130 countries are pursuing a master's or doctoral degree in one of six disciplines: management, information technology, law, health, psychology, and education.

Whilst maintaining the same high academic standards as expected as the on-campus equivalent degrees, the University's online programmes offer a distinctly global perspective and stimulating educational experience delivered in small, flexible, virtual classrooms.

With a proud history of promoting public health through practice and research, the University's Department of Public Health is recognised for excellence across a range of public health topics. The Master of Public Health (MPH) programme, offered as a general degree or in combination with one of three specialisations, provides a firm foundation in the science and art of promoting health and preventing disease while broadening the student's professional and personal horizons.



'Students who do the MPH are incredibly motivated,' says Dr Francine Watkns, MPH Programme Director, 'We have nurses, occupational therapists, doctors, surgeons, dentists, environmental health officers, and professionals who want to move into public health from a different background. They are all people who really want to make a difference both within

their own lives and within the communities in which they live and work.'

The University of Liverpool's health portfolio includes:

- MPH, including specialisations in Epidemiology; International Public Health; and Management of Health Systems;
- MSc in Clinical Research;
- MSc in Applied Psychology, including specialisations in General Psychology; and Mental Health;

- MSc in Forensic Psychology and Criminal Investigation.

Visit www.ohecampus.com today to learn more about the University of Liverpool's master's and doctoral degrees.



The Medicines for Malaria Venture (MMV) is recognised as the leading product development partnership (PDP) in the field of antimalaria drug research and development. It was established as a foundation in 1999, and registered in Switzerland.

Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing, and facilitating delivery of new, effective, and affordable antimalaria drugs.

MMV's strength comes from its product development partnership (PDP) model reflected in its network of more than 170 pharmaceutical, academic and endemic-country partners in 45 countries. MMV also works in close partnership with a number of WHO programmes that include TDR, the Global Malaria Programme (GMP), and Roll Back Malaria (RBM).

The key to its success lies in the focus of its mission, and the diversity of its team of almost 50 personnel from more than 20 countries. It manages over US\$515 million received and committed from long-term donors such as government agencies, private foundations, international organisations, and corporate foundations. In addition, it receives in-kind donations in the form of staff, facilities, and technology from its industry partners, estimated to be equal in dollar value to the funds from donors.

MMV is currently managing the largest portfolio of antimalarial R&D projects ever assembled. Of over 50 promising projects, one MMV-supported artemisinin combination therapy (ACT), Pyramax®, is awaiting regulatory approval by the European Medicines Agency (EMA) in 2012. In October 2011, dihydroartemisinin-piperaquine (Eurartesim®), an ACT developed in partnership with sigma-tau, was granted regulatory approval by the EMA and in November 2010, Guilin's artesunate injection for the treatment of severe malaria was approved by the WHO's Prequalification programme with assistance from MMV. In addition, Coartem® Dispersible, a child-friendly version of the ACT Coartem, was developed by Novartis in partnership with MMV and launched in 2009. Since then, more than 92 million courses of treatment have been supplied to 35 malaria-endemic countries.